UNSPSC 51263304: Butocrolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C19H23NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F63SY70KV0, chemically known as 9-(3-(tert-butylamino)-2-hydroxypropoxyl)-4-hydroxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one. but generally known as butocrolol, which bears US NIH Compound Identifier 189906. European Medicines Agency schedules Butocrolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06027MIG.

UNSPSC 51263304 Butocrolol, a Commodity code, covers pharmaceutical products used in emergency medical response and public health interventions. The code captures state and local procurement of prescription and over-the-counter medications in specific therapeutic categories, though recent activity shows the taxonomy applied here reflects a mismatch between the nominal code and the actual work being solicited. Issuing bodies under this code include county health departments and public health agencies managing emergency response and community health initiatives.

The recent opportunity shows minimal relevant activity under this code. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. Vendors must submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs, and comply with drug-free workplace certification, E-Verify requirements, and federal compliance standards if FEMA funding applies. The contract runs two years with an optional one-year renewal and includes a three-month probationary termination clause. However, the UNSPSC code designation appears inconsistent with the solicitation's actual scope—naloxone and drug deactivation systems fall outside the nominal butocrolol classification—suggesting the code does not reliably reflect current state and local demand in this therapeutic area or that the tagging reflects a data-entry variance rather than active procurement volume.